Characteristics
|
No.
|
5-year OS, %
|
P-value
|
---|
Chemotherapy
| | |
0.245
|
No/Unknown
|
925
|
50.2
| |
Yes
|
925
|
45.8
| |
Age, year
| | |
< 0.001
|
≤ 45
|
342
|
51.5
| |
45–65
|
1007
|
49.3
| |
> 65
|
501
|
43.1
| |
Race
| | |
0.833
|
White
|
1561
|
48.9
| |
Non-white
|
289
|
43.3
| |
Stage
| | |
0.354
|
IA
|
974
|
50.2
| |
IB
|
106
|
49.1
| |
IC
|
602
|
47.0
| |
IIA
|
168
|
38.1
| |
Grade
| | |
0.908
|
1
|
1176
|
51.2
| |
2
|
674
|
42.4
| |
Laterality
| | |
0.163
|
Right
|
790
|
46.7
| |
Left
|
806
|
50.5
| |
Other/Unknown
|
254
|
44.1
| |
Tumor size, cm
| | |
0.014
|
≤ 10
|
830
|
45.5
| |
> 10
|
777
|
44.8
| |
Unknown
|
243
|
66.7
| |
Histology
| | |
< 0.001
|
Serous
|
490
|
38.4
| |
Endometrioid
|
1360
|
51.5
| |
- P < 0.05 was considered to indicate a statistically significant difference. OS overall survival